Eli Lilly and Company filed an 8-K press release on November 14, 2026, announcing new clinical and real-world data presentations across its cardiometabolic health portfolio at ObesityWeek 2026, held November 14 to 17, 2026, in Washington, D.C.

Key Highlights

  • EloraTZP weight loss: Phase 2 results showed EloraTZP delivered weight loss of up to an average of 54.1 lbs (23.3%) at 48 weeks from an average baseline of 232.4 lbs in adults with obesity or overweight and type 2 diabetes.
  • EloraTZP A1C reduction: EloraTZP lowered A1C by up to an average of 2.9%, with up to 77% of participants achieving normal blood sugar levels, according to the filing.
  • Retatrutide and sleep apnea: In TRIUMPH-1, retatrutide reduced AHI by up to an average of 36.1 events per hour (60.6%) at 80 weeks; in TRIUMPH-2, the reduction was up to an average of 28.4 events per hour (48.1%) at 80 weeks.
  • Retatrutide and knee pain: TRIUMPH-4 results showed retatrutide reduced WOMAC pain by up to an average of 4.5 points (75.8%) at 68 weeks in adults with knee osteoarthritis pain and obesity or overweight.
  • Foundayo real-world survey: In the FOUNDERS survey, 96-98% of participants agreed the once-daily pill was simple, convenient, and easy to use, regardless of when, how, or with what they took it.
  • Eloralintide patient-reported outcomes: At 48 weeks, 74% of eloralintide-treated participants reported fewer food cravings, 52% reported less food noise, and 41% of those who drank alcohol at baseline reported drinking less.

Lilly's ObesityWeek 2026 Data Across Investigational and Approved Medicines

According to the filing, Eli Lilly and Company (NYSE:LLY) disclosed a series of presentations at ObesityWeek 2026 spanning Phase 2 and Phase 3 clinical trial results, patient-reported outcomes, and real-world evidence. An oral session on Sunday, November 15, 2026, from 3:30 to 4:30 p.m. ET covered EloraTZP, described in the filing as an investigational combination of eloralintide and tirzepatide. Phase 2 results showed that up to 60% of participants no longer met the BMI criteria for obesity at 48 weeks, in addition to the reported weight loss and A1C reductions.

A second oral session on November 15, 2026, from 5:00 to 6:30 p.m. ET covered retatrutide and Zepbound (tirzepatide). The filing describes retatrutide as an investigational once-weekly GIP, GLP-1, and glucagon triple receptor agonist. In TRIUMPH-1, retatrutide also reduced WOMAC knee osteoarthritis pain by up to an average of 4.3 points (73.1%) at 80 weeks. Separately, results from SURMOUNT-ADOLESCENTS showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 years with obesity, with more than half no longer meeting BMI criteria for obesity at 72 weeks, the filing stated.

The filing also reported poster presentations on Foundayo (orforglipron) and eloralintide. The filing notes that about 40% of FOUNDERS survey participants took Foundayo in the evening, afternoon, or at bedtime, and most took it with food, beverages, or other oral medications. The filing further disclosed that eloralintide is an investigational once-weekly selective amylin receptor agonist, with Phase 3 trials currently ongoing, and that retatrutide "is an investigational molecule that cannot be legally sold or marketed for human use."

What Was Disclosed

Eli Lilly disclosed Phase 2 and Phase 3 clinical data, real-world survey results, and patient-reported outcomes for EloraTZP, retatrutide, Zepbound, Foundayo, and eloralintide, to be presented at ObesityWeek 2026 from November 14 to 17, 2026, in Washington, D.C.